Last reviewed 2026-05-29 · How we verify

vormatrogine

Praxis Precision Medicines · Phase 3 active Small molecule ✓ Verified May 2026

vormatrogine is a Small molecule drug developed by Praxis Precision Medicines. It is currently in Phase 3 development.

Vormatrogine is being studied in clinical trials for the treatment of various types of epilepsy, including tonic-clonic, focal seizure, primary generalized seizure, and focal epilepsy. The trials involve administering vormatrogine at doses of 40 mg/day and 30 mg/day for 12 weeks.

Likelihood of approval

58.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	vormatrogine
Sponsor	Praxis Precision Medicines
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 3

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Clinical Trial of Vormatrigine in Adult Patients With Epilepsy (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

vormatrogine CI brief — competitive landscape report
vormatrogine updates RSS · CI watch RSS
Praxis Precision Medicines portfolio CI

Frequently asked questions about vormatrogine

What is vormatrogine?

vormatrogine is a Small molecule drug developed by Praxis Precision Medicines.

Who makes vormatrogine?

vormatrogine is developed by Praxis Precision Medicines (see full Praxis Precision Medicines pipeline at /company/praxis-precision-medicines).

What development phase is vormatrogine in?

vormatrogine is in Phase 3.

Manufacturer: Praxis Precision Medicines — full pipeline
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing